HIV & AIDS - Treatment & Care (medical)
Questions
In Progress
ID |
Question |
Subject |
Answer |
| 1956 |
|
Drug use | No answer yet |
| 1923 |
|
Preventive care | No answer yet |
| 1932 |
|
Preventive care | No answer yet |
| 1975 |
|
Аутрич - работник из ОГПР | No answer yet |
Answered
|
ID |
Question |
Subject |
Answer |
| 1012 |
|
A child is HIV+, has juvenile cerebral palsy |
|
| 1016 |
|
A family of PLHIV |
|
| 1023 |
|
A group of PLHIV |
|
| 1953 |
|
A need to learn more |
|
| 1037 |
|
A vaccine against HIV |
|
Total number: 377 ( More )
Publications
| Title |
 Authors |
Publication |
Page(s) | Link / File | |
|---|---|---|---|---|---|
| New WHO guidelines on PMTCT and infant feeding | World Health Organisation | www.aidsmap.com |
:
|
||
| New recommendations from the World Health Organization (WHO) for preventing mother-to-child transmission (PMTCT) have the potential to improve child survival and the mother’s own health, to reduce mother-to-child transmission risk to 5% or lower and virtually eliminate paediatric HIV infection, WHO said today. | |||||
| Timing of Initiation of Antiretroviral Drugs | Salim S. Abdool Karim, M.B., Ch.B., Ph.D., Kogieleum Naidoo, M.B., Ch.B., | NEJM | 697-706 |
:
|
|
| The initiation of antiretroviral therapy during tuberculosis therapy significantly improved survival and provides further impetus for the integration of tuberculosis and HIV services. (ClinicalTrials.gov number, NCT00398996.) | |||||
| Long-Term Effectiveness of Highly Active Antiretroviral Therapy on the Survival of Children and Adolescents with HIV Infection: A 10-Year Follow-Up Study | Patel, et al., | Clinical Infectious Diseases | (2008) 46 (4): 507-515. |
:
|
|
| Background. Previous observational studies found highly active antiretroviral therapy (HAART) to be associated with improved survival among human immunodeficiency virus (HIV)– infected children and adolescents. However, these studies had limited follow-up of HIV-infected children undergoing HAART. Given that HIV infection is chronic and that exposure to HAART is likely to be life-long, there is a need to evaluate the long-term effect of HAART on survival in this population. Methods. The study included 1236 children and adolescents who were perinatally infected with HIV, who were on study or enrolled after January 1996 in a United States-based multicenter prospective cohort study (Pediatric AIDS Clinical Trials Group 219/219C), and who were not receiving HAART at baseline; subjects were observed for a maximum of 10 years through June 2006. A weighted Cox regression model was used to estimate the effect of HAART on survival, appropriately adjusted for time-varying confounding by severity. Results. At the end of the 10-year follow-up period (median duration of follow-up, 6.3 years; interquartile range, 4.3– 9.8 years), 70% of participants had initiated HAART. Lower CD4 cell percentages, total lymphocyte counts, and albumin levels were associated with an increased probability of initiating HAART. Eighty-five deaths were observed, and the mortality hazard ratio associated with HAART, compared with non-HAART regimens, was 0.24 after adjusting for measured confounding by severity (95% confidence interval, 0.11– 0.51). Conclusions. The use of HAART was highly effective in reducing mortality during the period 1996– 2006 among children and adolescents infected with HIV. With improved long-term survival, continued follow-up is necessary to evaluate the effects of prolonged use of HAART on potential adverse events, immune function, growth, sexual maturation, and quality of life in this population. | |||||
| Surgery in Patients with HIV | HIV InSite | 0 |
:
|
||
| HIV InSite | |||||
| Guidelines for the Use of Antiretroviral | DHHS | On line | 116 |
:
|
|
| No abstract | |||||
Total number: 16 ( More )
